TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating reissued by stock analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports.
Several other analysts have also recently issued reports on TMDX. Oppenheimer increased their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Finally, Piper Sandler restated an "overweight" rating and set a $125.00 target price (up from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $128.70.
Get Our Latest Report on TMDX
TransMedics Group Stock Performance
TMDX traded up $1.07 on Tuesday, hitting $129.81. The company's stock had a trading volume of 789,937 shares, compared to its average volume of 1,358,819. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37. The firm has a market cap of $4.39 billion, a P/E ratio of 138.10 and a beta of 2.10. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company's 50 day simple moving average is $97.54 and its 200-day simple moving average is $79.14.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. During the same period last year, the company earned $0.35 earnings per share. The business's revenue for the quarter was up 48.2% on a year-over-year basis. Analysts forecast that TransMedics Group will post 1 EPS for the current year.
Insider Buying and Selling
In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 732 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,732 shares of company stock valued at $1,416,710 over the last three months. 7.00% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. purchased a new stake in TransMedics Group during the 1st quarter valued at $25,000. Smartleaf Asset Management LLC raised its holdings in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after purchasing an additional 135 shares during the period. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group during the fourth quarter valued at about $31,000. Hager Investment Management Services LLC bought a new stake in TransMedics Group during the 4th quarter worth approximately $33,000. Finally, Quarry LP lifted its stake in shares of TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after buying an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles

Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.